NASDAQ · REPL
Replimune Group, Inc.
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
Price chart by TradingView
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarThe next earnings date for REPL has not been announced yet.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Dec 2026 | $-0.66 | $-0.50 | $-0.83 | 4 |
| Mar 2027 | $-0.63 | $-0.41 | $-0.84 | 4 |
| Jun 2027 | $-0.52 | $-0.32 | $-0.73 | 3 |
| Sep 2027 | $-0.47 | $-0.28 | $-0.65 | 3 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
The Motley Fool · RTTNews · Fintel · BNK Invest- The Motley Fool · Oct 28, 9:33 PM EDTReplimune: 3 Key Takeaways for Long-Term InvestorsReplimune ended the second quarter with $307.8 million in cash.
- The Motley Fool · Oct 28, 6:44 PM EDTReplimune (REPL) Q2 2027 Earnings Call Transcript@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The Mo
- RTTNews · Oct 28, 3:16 PM EDTBiotech Stocks Rise: GMAB Surges, LUNG And AXGN Gain Over 30%(RTTNews) – Shares of several biotech companies moved higher following quarterly financial results, clinical trial developments and business updates. Genmab reported positive Phase 3 results for its cancer drug combination, Pulmonx posted improved quarterly results, Axogen and Or
- Fintel · Oct 28, 11:43 AM EDTReplimune Group, Inc. Reports Fiscal Second Quarter 2027 Financial Results and TUDRIQEV LaunchReplimune Group, Inc. announced its financial results for the fiscal second quarter ended September 30, 2026, and provided a corporate update. The company highlighted the commercial launch of TUDRIQEV (vusolimogene oderparepvec-wtpg), which was first delivered to patients for adv
- RTTNews · Oct 28, 8:13 AM EDTReplimune Posts Narrower Loss In Q2(RTTNews) – Replimune Group, Inc. (REPL) on Wednesday reported a narrower loss in the second quarter due to a decline in operating expenses. The company also provided several clinical and business updates.
- BNK Invest · Oct 27, 3:23 PM EDTNotable Tuesday Option Activity: MCY, INSM, REPLAmong the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Mercury General Corp. (Symbol: MCY), where a total of 2,961 contracts have traded so far, representing approximately 296,100 underlying shares. That amounts to about 96.
- Fintel · Sep 15, 6:00 PM EDTReplimune Group Consensus Price Target Increased by 29.5% to $19.55The average one-year price target for Replimune Group (NASDAQGS:REPL) has been revised to $19.55 / share. This is an increase of 29.50% from the prior estimate of $15.10 dated August 25, 2026. These figures represent the aggregate target of multiple analysts and do not constitut
- RTTNews · Sep 11, 11:45 AM EDTNew FDA Drug Approvals – August 2026(RTTNews) – The U.S. Food and Drug Administration (FDA) granted approval to 13 drugs last month, comprising both new drug approvals and expanded indications for previously approved therapies.
- RTTNews · Aug 11, 4:23 AM EDTReplimune Prices $150 Million Underwritten Offering(RTTNews) – Replimune Group, Inc. (REPL), a commercial-stage biotechnology company developing oncolytic immunotherapies, announced the pricing of an underwritten offering of 9,701,490 shares of its common stock at $12.06 per share.
- Zacks · Aug 10, 10:17 AM EDTHere's Why Replimune Stock Skyrockets Nearly 223% in 3 MonthsREPL's RP1 secures FDA approval for advanced melanoma, easing regulatory uncertainty. The company expands its oncolytic immunotherapy pipeline.
- RTTNews · Aug 7, 11:45 AM EDTWeekly Buzz: MRNA, NVS, SNY Gain Approvals; EBS, LSTA Cut Jobs; TARS, BIVI Drive Deals & Data(RTTNews) – This week's biotech roundup captured a mix of regulatory wins, restructuring action, and deal momentum driving sector sentiment. FDA and EU approvals spanned oncology, vaccines and rare disease, while layoffs and cost-saving measures underscored operational tightening
- RTTNews · Aug 7, 12:44 AM EDTReplimune Wins FDA Accelerated Nod For TUDRIQEV In Advanced Melanoma(RTTNews) – Replimune Group, Inc. (REPL) announced that the U.S. FDA has granted accelerated approval for TUDRIQEV, in combination with Nivolumab (Bristol Myers Squibb), for adults with unresectable advanced cutaneous melanoma who have progressed following anti-PD-1 antibody-base
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Company profile by TradingView
Financials
Loading fundamental data…
Fundamental data by TradingView
More headlines
More stories for Replimune Group, Inc. from TradingView. Coverage varies.
Loading related news…
Related news by TradingView
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.